Literature DB >> 23592279

Chemotherapy for extensive-stage small-cell lung cancer with idiopathic pulmonary fibrosis.

Naohiro Watanabe1, Hiroyuki Taniguchi, Yasuhiro Kondoh, Tomoki Kimura, Kensuke Kataoka, Osamu Nishiyama, Masashi Kondo, Yoshinori Hasegawa.   

Abstract

BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is associated with an independent increased risk of lung carcinogenesis. The benefit of chemotherapy for extensive-stage small-cell lung cancer (ED-SCLC) in cases of IPF remains unknown. This study was conducted to elucidate the efficacy of chemotherapy for ED-SCLC in patients with IPF.
METHODS: This was a retrospective observational study of ED-SCLC patients with IPF (all with distant metastasis) who received systemic chemotherapy. The response rate, toxicity, overall survival, and progression-free survival (PFS) were investigated.
RESULTS: Eleven patients treated with chemotherapy between January 2005 and December 2011 were the subjects of this study. The overall response rate with the 1st regimen was 63.6 %. The median overall survival was 7.0 months, and the median PFS was 4.7 months.
CONCLUSION: Our results suggest that ED-SCLC patients with IPF may benefit from chemotherapy. A prospective study will be needed to confirm this in the future.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23592279     DOI: 10.1007/s10147-013-0554-5

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN: 1341-9625            Impact factor:   3.402


  27 in total

1.  Prognostic significance of preexisting interstitial lung disease in Japanese patients with small-cell lung cancer.

Authors:  Yosuke Togashi; Katsuhiro Masago; Tomohiro Handa; Kiminobu Tanizawa; Chiyuki Okuda; Yuichi Sakamori; Hiroki Nagai; Young Hak Kim; Michiaki Mishima
Journal:  Clin Lung Cancer       Date:  2011-12-13       Impact factor: 4.785

2.  Idiopathic interstitial pneumonias: diagnostic accuracy of thin-section CT in 129 patients.

Authors:  T Johkoh; N L Müller; Y Cartier; P V Kavanagh; T E Hartman; M Akira; K Ichikado; M Ando; H Nakamura
Journal:  Radiology       Date:  1999-05       Impact factor: 11.105

3.  Basis of acute exacerbation of idiopathic pulmonary fibrosis in Japanese patients.

Authors:  Arata Azuma; Koichi Hagiwara; Shoji Kudoh
Journal:  Am J Respir Crit Care Med       Date:  2008-06-15       Impact factor: 21.405

4.  The risk of cytotoxic chemotherapy-related exacerbation of interstitial lung disease with lung cancer.

Authors:  Hirotsugu Kenmotsu; Tateaki Naito; Madoka Kimura; Akira Ono; Takehito Shukuya; Yukiko Nakamura; Asuka Tsuya; Kyoichi Kaira; Haruyasu Murakami; Toshiaki Takahashi; Masahiro Endo; Nobuyuki Yamamoto
Journal:  J Thorac Oncol       Date:  2011-07       Impact factor: 15.609

5.  Lung cancer in patients with idiopathic pulmonary fibrosis.

Authors:  J Park; D S Kim; T S Shim; C M Lim; Y Koh; S D Lee; W S Kim; W D Kim; J S Lee; K S Song
Journal:  Eur Respir J       Date:  2001-06       Impact factor: 16.671

6.  Idiopathic pulmonary fibrosis: a disease with similarities and links to cancer biology.

Authors:  C Vancheri; M Failla; N Crimi; G Raghu
Journal:  Eur Respir J       Date:  2010-03       Impact factor: 16.671

Review 7.  Lung cancer in pulmonary fibrosis: tales of epithelial cell plasticity.

Authors:  Melanie Königshoff
Journal:  Respiration       Date:  2011-04-19       Impact factor: 3.580

8.  [Ifosfamide versus ifosfamide + CCNU in the treatment of inoperable small cell carcinoma of the lung. A clinical study].

Authors:  O Kokron; M Micksche; R Titscher; H Wrba
Journal:  Onkologie       Date:  1982-04

9.  Phase III study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapy-naive patients with extensive-stage small-cell lung cancer.

Authors:  Mark A Socinski; Egbert F Smit; Paul Lorigan; Kartik Konduri; Martin Reck; Aleksandra Szczesna; Johnetta Blakely; Piotr Serwatowski; Nina A Karaseva; Tudor Ciuleanu; Jacek Jassem; Mircea Dediu; Shengyan Hong; Carla Visseren-Grul; Axel-Rainer Hanauske; Coleman K Obasaju; Susan C Guba; Nick Thatcher
Journal:  J Clin Oncol       Date:  2009-08-31       Impact factor: 44.544

10.  Acute exacerbation of interstitial pneumonia associated with collagen vascular diseases.

Authors:  Takafumi Suda; Yusuke Kaida; Yutaro Nakamura; Noriyuki Enomoto; Tomoyuki Fujisawa; Shiro Imokawa; Hideo Hashizume; Tateaki Naito; Dai Hashimoto; Yasuo Takehara; Naoki Inui; Hirotoshi Nakamura; Thomas V Colby; Kingo Chida
Journal:  Respir Med       Date:  2009-02-01       Impact factor: 3.415

View more
  11 in total

Review 1.  Lung cancer and interstitial lung disease: a literature review.

Authors:  Jean-Marc Naccache; Quentin Gibiot; Isabelle Monnet; Martine Antoine; Marie Wislez; Christos Chouaid; Jacques Cadranel
Journal:  J Thorac Dis       Date:  2018-06       Impact factor: 2.895

2.  Risk of pneumonitis in non-small cell lung cancer patients with preexisting interstitial lung diseases treated with immune checkpoint inhibitors: a nationwide retrospective cohort study.

Authors:  Kenji Sawa; Izumi Sato; Masato Takeuchi; Koji Kawakami
Journal:  Cancer Immunol Immunother       Date:  2022-08-22       Impact factor: 6.630

3.  Real world data of combined lung cancer and interstitial lung disease.

Authors:  Tatsuo Kawahara; Hiroyuki Sakashita; Takafumi Suzuki; Tomoya Tateishi; Yasunari Miyazaki
Journal:  J Thorac Dis       Date:  2019-10       Impact factor: 2.895

4.  Prognosis of Small Cell Lung Cancer with Idiopathic Pulmonary Fibrosis: Assessment according to GAP Stage.

Authors:  Myung Jin Song; Sung Yoon Lim; Jong Sun Park; Ho Il Yoon; Jae-Ho Lee; Song Yee Kim; Ji Ye Jung; Young Ae Kang; Moo Suk Park; Young Sam Kim; Joon Chang; Sang Hoon Lee; Choon-Taek Lee
Journal:  J Oncol       Date:  2019-05-02       Impact factor: 4.375

5.  Idiopathic pulmonary fibrosis in small cell lung cancer as a predictive factor for poor clinical outcome and risk of its exacerbation.

Authors:  Nobuyuki Koyama; Yuki Iwai; Yoshiaki Nagai; Kazutetsu Aoshiba; Hiroyuki Nakamura
Journal:  PLoS One       Date:  2019-08-23       Impact factor: 3.240

6.  [A Review of Drug Therapy of Lung Cancer with Interstitial Lung Disease].

Authors:  Yanning Wang; Yujie Zhou; Liyun Miao
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2020-04-20

7.  Impact of idiopathic pulmonary fibrosis on clinical outcomes of lung cancer patients.

Authors:  Ho Cheol Kim; Seonjeong Lee; Jin Woo Song
Journal:  Sci Rep       Date:  2021-04-15       Impact factor: 4.379

8.  Rationale and protocol design for the TORG1835/NEXT-SHIP study: a phase II study of carboplatin, etoposide and nintedanib for unresectable limited/extensive disease small cell lung cancer with idiopathic pulmonary fibrosis.

Authors:  Satoshi Ikeda; Takashi Ogura; Terufumi Kato; Hirotsugu Kenmotsu; Tae Iwasawa; Toshihiro Misumi; Takeharu Yamanaka; Hiroaki Okamoto
Journal:  Ther Adv Med Oncol       Date:  2020-05-18       Impact factor: 8.168

9.  Identification of common signatures in idiopathic pulmonary fibrosis and lung cancer using gene expression modeling.

Authors:  Dong Leng; Jiawen Yi; Maodong Xiang; Hongying Zhao; Yuhui Zhang
Journal:  BMC Cancer       Date:  2020-10-12       Impact factor: 4.430

10.  Glasgow prognostic score for prediction of chemotherapy-triggered acute exacerbation interstitial lung disease in patients with small cell lung cancer.

Authors:  Ryota Kikuchi; Hiroyuki Takoi; Takao Tsuji; Yoko Nagatomo; Akane Tanaka; Hayato Kinoshita; Mariko Ono; Mayuko Ishiwari; Kazutoshi Toriyama; Yuta Kono; Yuki Togashi; Kazuhiro Yamaguchi; Akinobu Yoshimura; Shinji Abe
Journal:  Thorac Cancer       Date:  2021-05-03       Impact factor: 3.500

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.